DZ2649A1 - Association des principes actifs pour le traitement de la démence sénile du type alzheimer. - Google Patents

Association des principes actifs pour le traitement de la démence sénile du type alzheimer.

Info

Publication number
DZ2649A1
DZ2649A1 DZ980259A DZ980259A DZ2649A1 DZ 2649 A1 DZ2649 A1 DZ 2649A1 DZ 980259 A DZ980259 A DZ 980259A DZ 980259 A DZ980259 A DZ 980259A DZ 2649 A1 DZ2649 A1 DZ 2649A1
Authority
DZ
Algeria
Prior art keywords
association
treatment
senile dementia
active principles
alzheimer type
Prior art date
Application number
DZ980259A
Other languages
English (en)
French (fr)
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DZ2649A1 publication Critical patent/DZ2649A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ980259A 1997-11-14 1998-11-11 Association des principes actifs pour le traitement de la démence sénile du type alzheimer. DZ2649A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
DZ2649A1 true DZ2649A1 (fr) 2004-12-28

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980259A DZ2649A1 (fr) 1997-11-14 1998-11-11 Association des principes actifs pour le traitement de la démence sénile du type alzheimer.

Country Status (27)

Country Link
EP (1) EP1030671A1 (xx)
JP (1) JP2001523642A (xx)
KR (1) KR100599350B1 (xx)
CN (1) CN1243540C (xx)
AU (1) AU743228B2 (xx)
BG (1) BG64819B1 (xx)
BR (1) BR9814035A (xx)
CA (1) CA2309966A1 (xx)
CO (1) CO4980891A1 (xx)
DZ (1) DZ2649A1 (xx)
EA (1) EA003255B1 (xx)
EE (1) EE04235B1 (xx)
HU (1) HUP0100098A3 (xx)
ID (1) ID24933A (xx)
IL (2) IL136122A0 (xx)
IS (1) IS5482A (xx)
MY (1) MY120461A (xx)
NO (1) NO20002450L (xx)
NZ (1) NZ504420A (xx)
OA (1) OA11464A (xx)
PL (1) PL194597B1 (xx)
SA (1) SA98190747B1 (xx)
SK (1) SK286040B6 (xx)
TR (1) TR200001262T2 (xx)
TW (1) TW585766B (xx)
UY (1) UY25247A1 (xx)
WO (1) WO1999025363A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
ES2327914T3 (es) * 2002-08-07 2009-11-05 Novartis Ag Metodo para pronosticar la sensibilidad al tratamiento con ravastigmina basado en el genotipo apoe de pacintes con demencia.
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
MX2019013524A (es) * 2017-05-15 2020-02-10 Cognition Therapeutics Inc Composiciones para tratar enfermedades neurodegenerativas.
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
PL185124B1 (pl) * 1995-03-06 2003-02-28 Interneuron Pharmaceuticals Zastosowanie cytykoliny oraz jej kompozycja do wytwarzania leku przeznaczonego do ochrony tkanki mózgowej
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
IL136122A (en) 2006-07-05
EE04235B1 (et) 2004-02-16
CA2309966A1 (en) 1999-05-27
NZ504420A (en) 2003-08-29
OA11464A (en) 2003-11-18
AU1160999A (en) 1999-06-07
BR9814035A (pt) 2000-09-26
TR200001262T2 (tr) 2001-01-22
SK286040B6 (sk) 2008-01-07
EP1030671A1 (fr) 2000-08-30
WO1999025363A1 (fr) 1999-05-27
EA200000412A1 (ru) 2000-12-25
PL194597B1 (pl) 2007-06-29
CN1285742A (zh) 2001-02-28
PL340500A1 (en) 2001-02-12
CN1243540C (zh) 2006-03-01
ID24933A (id) 2000-08-31
AU743228B2 (en) 2002-01-24
BG104428A (en) 2001-08-31
BG64819B1 (bg) 2006-05-31
KR20010032099A (ko) 2001-04-16
CO4980891A1 (es) 2000-11-27
NO20002450D0 (no) 2000-05-11
SK7112000A3 (en) 2000-10-09
EE200000290A (et) 2001-06-15
TW585766B (en) 2004-05-01
IS5482A (is) 2000-05-09
HUP0100098A3 (en) 2001-12-28
SA98190747B1 (ar) 2006-11-04
UY25247A1 (es) 2001-05-31
EA003255B1 (ru) 2003-02-27
JP2001523642A (ja) 2001-11-27
HUP0100098A2 (hu) 2001-07-30
NO20002450L (no) 2000-07-14
KR100599350B1 (ko) 2006-07-12
MY120461A (en) 2005-10-31
IL136122A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
ATE279407T1 (de) Fsh mimetika zur behandlung von infertilität
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2718351B1 (fr) Procédé pour la déformation permanente des matières kératiniques.
FR2721823B1 (fr) Procede pour la deformation permanente des matieres keratiniques
DZ2649A1 (fr) Association des principes actifs pour le traitement de la démence sénile du type alzheimer.
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
DE69607728D1 (de) Thixogussverfahren
MA22649A1 (fr) Procede de preparation de composes pour le traitement des maladies en rapport avec le leucotriene .
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
FR2684546B3 (fr) Instrument de traitement, en particulier pour le traitement cosmetique du visage.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2719240B1 (fr) Procédé de traitement des suspensions huileuses.
FR2771007B1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR2771006B1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
FR2713657B1 (fr) Nouveaux vecteurs pour le traitement du sida.
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
FR2680123B1 (fr) Procede de traitement de residus fortement polluants pour l'environnement.
FR2716803B1 (fr) Procédé pour la déformation permanente des matières kératiniques.
FR2806293B1 (fr) Implants scleraux pour le traitement du decollement de retine
FR2694748B1 (fr) Décanteur-digesteur pour le traitement des eaux ménagères de rejet.
FR2702645B1 (fr) Baignoire adaptable pour salle de bains.